Robert Hershberg, M.D, Ph.D., is a member of Silverback Therapeutics’ board of directors. He currently serves as executive vice president and head of business development and global alliances at Celgene, where he was previously chief scientific officer. Prior to joining Celgene, Dr. Hershberg was the co-founder and chief executive officer of VentiRx Pharmaceuticals. Earlier in his career, he was the chief medical officer of Dendreon and vice president of medical genetics at Corixa. He began his career in academia, having served as an assistant professor at Harvard Medical School. He also serves on the Boards of Adaptive Biotechnologies and Nanostring Technologies. Dr. Hershberg holds an M.D. from UCLA and a Ph.D. from the Salk Institute.